New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amisulpride 50mg;   - tablet - 50 mg - active: amisulpride 50mg   excipient: lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rivopharm (uk) ltd - amisulpride - oral tablet - 50mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; methylcellulose; magnesium stearate; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; methylcellulose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; methylcellulose; lactose monohydrate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: macrogol 6000; methylcellulose; purified talc; magnesium stearate; sodium starch glycollate type a; microcrystalline cellulose; basic butylated methacrylate copolymer; titanium dioxide; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - amisulpride - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - amisulpride - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - amisulpride - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - amisulpride - oral tablet - 50mg